The Phenylketonuria (PKU) Treatment Market is estimated to be valued at US$445.8 million in 2023 and is expected to exhibit a CAGR of 11.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Phenylketonuria (PKU) is a rare genetic disorder that affects the metabolism of the amino acid phenylalanine. The accumulation of phenylalanine in the body can lead to intellectual disabilities and other neurological problems. The market for PKU treatment is driven by the increasing prevalence of the disease and the advancements in treatment modalities. Currently, the mainstay of treatment for PKU includes a strict low-protein diet and the use of special medical formulas that are low in phenylalanine. Additionally, advancements in gene therapy and enzyme replacement therapies are expected to further drive market growth.
The rising prevalence of PKU worldwide is a major driver for market growth. According to the National PKU Alliance, PKU affects approximately 1 in 10,000 to 1 in 15,000 individuals in the United States. Moreover, technological advancements in the development of novel treatment modalities, such as gene therapy and enzyme replacement therapies, are expected to drive market growth. These innovative therapies have the potential to provide long-term relief to PKU patients by correcting the underlying genetic defect or supplementing deficient enzymes. These factors, coupled with increasing awareness about PKU and its treatment options, are expected to fuel market growth over the forecast period.
– BioMarin Pharmaceutical Inc., Dimension Therapeutics, Inc., and American Gene Technologies International Inc. are key players in the Phenylketonuria Treatment market, which strengthens the market’s competitive landscape.
– The market is expected to witness high growth with a CAGR of 11.0% over the forecast period, indicating a positive outlook for the market.
– Phenylketonuria treatment market is driven by increasing awareness about the condition, advancements in medical technology, and the growing number of research and development activities.
– Limited availability of treatment options for Phenylketonuria (PKU) patients is a significant weakness in the market.
– High treatment costs and limited reimbursement for PKU treatment can negatively impact the market growth.
– There is a significant opportunity for market players to develop innovative and effective treatments for Phenylketonuria, addressing the unmet medical needs of patients.
– The increasing prevalence of PKU worldwide offers a potential market expansion opportunity to pharmaceutical companies.
– Stringent regulations and complex approval processes for new treatments can pose a threat to market growth.
– The presence of alternative treatment options for PKU, such as dietary management and gene therapy, can pose a competitive threat to the market.
The Global Phenylketonuria Treatment Market Demand is expected to witness high growth, exhibiting a CAGR of 11.0% over the forecast period, due to increasing awareness about the condition, technological advancements, and research and development activities. The market’s regional analysis shows that North America is the fastest-growing and dominating region, attributed to the presence of key market players and growing investments in healthcare. The key players operating in the Phenylketonuria Treatment market include BioMarin Pharmaceutical Inc., Dimension Therapeutics, Inc., American Gene Technologies International Inc., Synthetic Biologics, Inc., Codexis, Inc., SOM Innovation Biotech SL, Daiichi Sankyo Company, Limited, and Erytech Pharma SA. These players contribute to the market’s competitiveness and strive to develop innovative treatments for Phenylketonuria.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it